About Us

Robert A. Baffi, president and founder of Baffi Biotech Advisors, a venture partner at Samsara BioCapital, and former president of global manufacturing and technical operations for BioMarin Pharmaceutical for 23 years. He also is co-author of the book, “Making a Habit of Quality: How Technical Operations Paved the Way for BioMarin’s Success.”

Mitchell E. Daniels, Jr., the 12th president of Purdue University and 49th governor of Indiana, who also served as director of the U.S. Office of Management and Budget in the George W. Bush administration. Earlier, he held two positions with Eli Lilly and Company — president of North American operations and senior vice president for corporate strategy and policy.

Michael A. Klobuchar, chief operating officer for Eikon Therapeutics, Inc., leads the biotech company’s corporate infrastructure, including global supply chain management and product manufacturing, and manages key executives across Eikon Systems, IT, facilities, and business operations across the enterprise. He previously served as executive vice president and chief strategy officer for Merck & Co., Inc., and as senior vice president and chief financial officer for Merck Research Laboratories, where he led its Global Portfolio and Alliance Management group, among other roles across the entire company. He received his BS in chemical engineering from Purdue in 1998.

Moheb M. Nasr, principal with Nasr Pharma Regulatory Consulting, who previously served as vice president of chemistry, manufacturing, controls and regulatory strategy for GlaxoSmithKline and as director of the Office of New Drug Quality Assessment for the Food and Drug Administration’s Center for Drug Evaluation and Research.

William D. Young, whose significant contribution established the Purdue institute named for him and his wife in June 2022, is a senior advisor at Blackstone Life Sciences. Previously he was Chairman of the Board of Biogen (NASDAQ: BIIB) and served as CEO of Monogram Biosciences, a leader in personalized medicine, from 1999 through to the sale of the company to LabCorp in 2009. Prior to Monogram, Young was at Genentech since 1980 at positions of increasing responsibility, including COO, responsible for all of the biotechnology company’s development, operations and commercial functions. Prior to Genentech, he was at Eli Lilly and Company for 14 years. Young received his Bachelor’s degree in Chemical Engineering from Purdue University, his MBA from Indiana University and an Honorary Doctorate in Engineering from Purdue University. In 1993 he was elected to the National Academy of Engineering for his leadership in research, development and manufacturing of recombinant proteins using recombinant DNA technology, pioneering large-scale production of biotech therapies.